BioSpace News Archive

ProQR Therapeutics NV. today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference.

BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace , Hillhouse Capital.

The International Myeloma Foundation, in partnership with the National Medical Association, the W. Montague Cobb Institute, and the Student National Medical Association, sent a delegation of eleven IMF Medical Student Scholars for Health Equity in Myeloma along with their mentors to the 2023 NMA Annual Convention and Scientific Assembly, which took place in New Orleans, LA from July 29-August 2, 2023.

Nexcella, Inc. today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman MD PhD and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.

Actinium Pharmaceuticals, Inc. today highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia (r/r AML) and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided an update on the continued advancement of ELX-02 for the treatment of Alport syndrome with nonsense mutations, including additional positive results from its Phase 2 clinical study evaluating ELX-02, as well as an update on ZKN-013.

SciSparc Ltd. today announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”) at the Tel Aviv Sourasky Medical Center in Israel (“Sourasky”).

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year.

Lucid Diagnostics Inc. today announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study.

Dr. Abdel Halim, Acutis Biosciences’ Chief Scientific Officer, one of a group who led the study FOENIX-CCA2 (funded by Taiho Oncology and Taiho Pharmaceutical), recently published results about Futibatinib (LYTGOBI®) in cholangiocarcinoma with FGFR2 gene rearrangements/fusions in the New England Journal of Medicine (NEJM).